MedicineNews.net - Medical Updates

Pembrolizumab for the treatment of non-small cell lung carcinoma

Immune checkpoint inhibitors targeting programmed death protein 1 ( PD-1 ) receptor and its ligand, PD-L1, have recently led to significant and durable improvements in the clinical outcomes of some ty ... read article

FDA has approved Afstyla, the first and only recombinant Factor VIII single chain therapy for hemophilia A

The FDA ( U.S. Food and Drug Administration ) has approved Afstyla [ Antihemophilic Factor ( Recombinant ), Single Chain ], a novel long-lasting recombinant factor VIII single-chain therapy for adults ... read article

PI3K/mTOR pathway as a potential therapeutic target for melanoma intrinsically resistant to BRAF inhibitors

Dysregulation of receptor tyrosine kinases ( RTKs ) contributes to several aspects of oncogenesis including drug resistance. In melanoma, distinct RTKs have been involved in BRAF inhibitors ( BRAFi ) ... read article

Giotrif, overall survival benefit for patients with EGFR mutation-positive non-small cell lung cancer

The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has issued a positive opinion for an update to the European label for Giotrif ( Afatinib ), strengt ... read article

Selumetinib, a MEK inhibitor, in combination with Dacarbazine does not effective in uveal melanoma

The phase 3 SUMIT study of Selumetinib in combination with Dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival. Th ... read article

BACE inhibitors: BI 1181181 voluntarily put on temporary clinical hold for safety evaluation

Vitae Pharmaceuticals has announced that its partner Boehringer Ingelheim has voluntarily placed BI 1181181 on a temporary clinical hold, and has notified regulatory agencies of its decision. BI 1 ... read article

COPD maintenance treatment, Spiolto Respimat approved in first European countries

Boehringer Ingelheim has announced regulatory authority approvals for Spiolto Respimat ( Tiotropium / Olodaterol ) in first European countries [ As of 29th June, Spiolto Respimat has been approved in ... read article

Cobimetinib in combination with Vemurafenib in patients with BRAF V600 mutation-positive advanced melanoma

Positive overall survival results from coBRIM, the phase 3 pivotal trial evaluating Cobimetinib, a specific MEK inhibitor, in combination with Vemurafenib in previously untreated patients with unresec ... read article

Lesinurad for treatment of hyperuricemia associated with gout, in combination with a xanthine oxidase inhibitor

The US Food and Drug Administration’s ( FDA ) Arthritis Advisory Committee ( AAC ) voted 10 to 4 to recommend the approval of Lesinurad 200mg tablets for the treatment of hyperuricemia associated with ... read article

Myocardial infarction: lower dosage of beta-blockers may decrease mortality

Patients treated with a lower dosage of beta-blockers following their myocardial infarction survived at the same rate, or even better rates, than patients on the high doses. More precisely, the patie ... read article

Combination of Sacubril and Valsartan for treatment of symptomatic chronic heart failure with reduced ejection fraction: CHMP has adopted a positive opinion

The Committee for Medicinal Products for Human Use ( CHMP ) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Entresto, intended for the trea ... read article

Locally advanced basal cell carcinoma: positive CHMP opinion for Odomzo

The CHMP ( Committee for Medicinal Products for Human Use ) has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Odomzo, intended for the tr ... read article

Advanced melanoma: positive CHMP opinion for Keytruda

The CHMP ( Committee for Medicinal Products for Human Use ) has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Keytruda, intended as monot ... read article

Severe asthma and tailored therapy

Patients with severe asthma or chronic obstructive pulmonary disease ( COPD ) have often a suboptimal symptom control due to inadequate treatment. A better understanding of pathogenetic mechanisms, ph ... read article

Specific reversal agent Idarucizumab led to immediate, complete and sustained reversal of Dabigatran in healthy individuals

The Lancet has published results from a healthy volunteer study investigating the reversal of the anticoagulant effect of Pradaxa ( Dabigatran etexilate ) by its specific reversal agent Idarucizumab. ... read article